Evidence map›Paper›PMID 23941761›Full record

Trial reportAmerican journal of nephrology2013

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

Michael E Seifert, Lisa de las Fuentes, Marcos Rothstein, Dennis J Dietzen, Andrew J Bierhals, Steven C Cheng, Will Ross, David Windus, Víctor G Dávila-Román, Keith A Hruska

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 6 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 6 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2017
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michael E SeifertDivision of Pediatric Nephrology, Southern Illinois University, Springfield, Ill., USA.
Lisa de las Fuentes
Marcos Rothstein
Dennis J Dietzen
Andrew J Bierhals
Steven C Cheng
Will Ross
David Windus
Víctor G Dávila-Román
Keith A Hruska
Core Laboratories (United States) · USPediatric Nephrology of Alabama · USMallinckrodt (United States) · USPediatrics and Genetics · US

Funding

Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Washington University Institute of Clinical and Translational Sciences (KL2)KL2RR024994 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$8.6M
RENAL OSTEODYSTROPHY AND VASCULAR CALCIFICATIONR01DK070790 · NIDDK · WASHINGTON UNIVERSITY · PI HRUSKA, KEITH A · 2006 to 2018
$3.9M
CARDIOVASCULAR RISK MECHANISMS IN CKDR01DK089137 · NIDDK · WASHINGTON UNIVERSITY · PI HRUSKA, KEITH A · 2012 to 2016
$1.6M
NCATS NIH HHS UL1 TR000448NCRR NIH HHS KL2 RR024994NCRR NIH HHS KL2RR024994NCRR NIH HHS UL1 RR024992NIDDK NIH HHS DK 070790NIDDK NIH HHS DK 089137NIDDK NIH HHS R01 DK070790NIDDK NIH HHS R01 DK089137
6 · The paper itself

Abstract

BACKGROUND/

aimsCardiovascular disease (CVD) is increased in chronic kidney disease (CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD-MBD begins in early CKD and its vascular manifestations begin with vascular stiffness proceeding to increased carotid artery intima-media thickness (cIMT) and vascular calcification (VC). Phosphorus is associated with this progression and is considered a CVD risk factor in CKD. We hypothesized that modifying phosphorus balance with lanthanum carbonate (LaCO3) in early CKD would not produce hypophosphatemia and may affect vascular manifestations of CKD-MBD.

methodsWe randomized 38 subjects with normophosphatemic stage 3 CKD to a fixed dose of LaCO3 or matching placebo without adjusting dietary phosphorus in a 12-month randomized, double-blind, pilot and feasibility study. The primary outcome was the change in serum phosphorus. Secondary outcomes were changes in measures of phosphate homeostasis and vascular stiffness assessed by carotid-femoral pulse wave velocity (PWV), cIMT and VC over 12 months.

resultsThere were no statistically significant differences between LaCO3 and placebo with respect to the change in serum phosphorus, urinary phosphorus, tubular reabsorption of phosphorus, PWV, cIMT, or VC. Biomarkers of the early CKD-MBD such as plasma fibroblast growth factor-23, Dickkopf-related protein 1 (DKK1), and sclerostin were increased 2- to 3-fold at baseline, but were not affected by LaCO3.

conclusionTwelve months of LaCO3 had no effect on serum phosphorus and did not alter phosphate homeostasis, PWV, cIMT, VC, or biomarkers of CKD-MBD.

Indexed as

Vascular StiffnessAgedBiomarkersCardiovascular DiseasesDiabetes ComplicationsDouble-Blind MethodFeasibility StudiesFemaleHomeostasisHumansLanthanumMaleMiddle AgedPhosphatesPhosphorusPhosphorus, DietaryBiomarkersLanthanumlanthanum carbonatePhosphatesPhosphorusPhosphorus, Dietary

Identifiers

PMID23941761
PMCPMC3874122
OpenAlexW1561791332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.